TY - JOUR
T1 - Inhibition of p600 expression suppresses both invasiveness and anoikis resistance of gastric cancer
AU - Sakai, Hiroshi
AU - Ohuchida, Kenoki
AU - Mizumoto, Kazuhiro
AU - Cui, Lin
AU - Nakata, Kohei
AU - Toma, Hiroki
AU - Nagai, Eishi
AU - Tanaka, Masao
N1 - Funding Information:
ACKNOWLEDGMENT Supported in part by a Grant-in-Aid from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and grants from the Japanese Society of Gastroenterology and Pancreas Research Foundation of Japan.
PY - 2011/7
Y1 - 2011/7
N2 - Background. Advanced gastric cancers often metastasize to distant organs and the peritoneum, leading to a poor prognosis. Both invasiveness and resistance to anchorageindependent cell death (anoikis) are important factors in the process of metastasis. p600 (600-kDa protein), recently identified from a cervical cancer cell line, plays a role in both anoikis resistance and cell migration. In this study, we examined whether p600 is involved in the progression of gastric cancer. Methods. We used both normal gastric mucosal cells and cancer cells laser-microdissected from 42 gastric cancers and their normal counterparts, and compared their p600 mRNA expression levels with quantitative reverse transcriptase-polymerase chain reaction. We inhibited p600 expression in two gastric cancer cell lines with siRNA and examined its effect on the invasiveness and anoikis resistance both in vitro and in vivo. Results. Expression of p600 mRNA was significantly higher in gastric cancer cells than in normal mucosal cells (P = 0.027). The invasion assay revealed that invasiveness was significantly reduced by inhibition of p600 (P<0.01). In vitro experiments revealed that cell viability and colonyformation capacity under anchorage-independent conditions were significantly reduced by inhibition of p600 (P<0.05). In vivo experiments also showed that the establishment of intraperitoneal disseminated tumors was significantly suppressed by transient inhibition of p600 (P<0.001). Conclusions. Our results strongly suggest that p600 is involved in gastric cancer progression, and has a potential to be a new molecular target for gastric cancer therapy.
AB - Background. Advanced gastric cancers often metastasize to distant organs and the peritoneum, leading to a poor prognosis. Both invasiveness and resistance to anchorageindependent cell death (anoikis) are important factors in the process of metastasis. p600 (600-kDa protein), recently identified from a cervical cancer cell line, plays a role in both anoikis resistance and cell migration. In this study, we examined whether p600 is involved in the progression of gastric cancer. Methods. We used both normal gastric mucosal cells and cancer cells laser-microdissected from 42 gastric cancers and their normal counterparts, and compared their p600 mRNA expression levels with quantitative reverse transcriptase-polymerase chain reaction. We inhibited p600 expression in two gastric cancer cell lines with siRNA and examined its effect on the invasiveness and anoikis resistance both in vitro and in vivo. Results. Expression of p600 mRNA was significantly higher in gastric cancer cells than in normal mucosal cells (P = 0.027). The invasion assay revealed that invasiveness was significantly reduced by inhibition of p600 (P<0.01). In vitro experiments revealed that cell viability and colonyformation capacity under anchorage-independent conditions were significantly reduced by inhibition of p600 (P<0.05). In vivo experiments also showed that the establishment of intraperitoneal disseminated tumors was significantly suppressed by transient inhibition of p600 (P<0.001). Conclusions. Our results strongly suggest that p600 is involved in gastric cancer progression, and has a potential to be a new molecular target for gastric cancer therapy.
UR - http://www.scopus.com/inward/record.url?scp=80051544744&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80051544744&partnerID=8YFLogxK
U2 - 10.1245/s10434-010-1523-0
DO - 10.1245/s10434-010-1523-0
M3 - Article
C2 - 21347795
AN - SCOPUS:80051544744
SN - 1068-9265
VL - 18
SP - 2057
EP - 2065
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 7
ER -